Drugs used in the treatment of cardiovascular disorders and diabetes are among the most commonly prescribed medications in the United States. Figures 1 and 2 show a classification of cardiovascular and antidiabetic medications. Use of these agents has continuously increased due to the improved recognition of these disorders and their complications. Additionally, the ever-growing problem of obesity and the metabolic syndrome has caused an increase in the incidence of diabetes, dyslipidemia, hypertension, and subsequent coronary artery disease and dysrhythmias. There is high prevalence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in patients with obesity, diabetes, and dyslipidemia, and distinguishing medication-induced liver disease from underlying liver disease can be difficult. This leads to difficulty in distinguishing whether the liver disease is due to cardiovascular or diabetic drugs themselves or is a manifestation of underlying liver disease resulting from metabolic disorders and diabetes. Evolving data suggest that patients with diabetes may have higher risk of drug-induced liver disease than nondiabetic individuals. Diabetic patients who take oral hypoglycemics have a higher risk of developing drug-induced liver disease than those not taking these medications (1,2). An excellent review was recently published by Wang and colleagues that provided a detailed review of existing human and animal studies supporting the notion that patients with diabetes are generally at higher risk for developing drug hepatotoxicity (3).
|Original language||English (US)|
|Title of host publication||Drug-Induced Liver Disease, Second Edition|
|Number of pages||38|
|State||Published - Jan 1 2007|
ASJC Scopus subject areas
- Pharmacology, Toxicology and Pharmaceutics(all)